...September 15, 2021 - Improvements to governance at Olympus have cut the risk that related issues will hurt its finances again; significant regulatory fines damaged profitability and key financial ratios in the past. - The company's key cash flow ratios are unlikely to improve substantially in the next two years or so, because it will likely accelerate growth investments as performance and cash flow increase. - We affirmed our '###+' long-term issuer credit rating on Olympus and the rating outlook remains stable. TOKYO (S&P Global Ratings) Sept. 15, 2021--S&P Global Ratings today said it has affirmed its '###+' long-term issuer credit rating on Japan-based medical technology company Olympus Corp. The rating outlook remains stable. We affirmed the rating because Olympus has over a number of years strengthened internal controls and improved governance, thereby reducing the risk of related issues recurring and hurting its finances. Its actions come after a sharp deterioration in profitability...
